Baxter Kidney Care becomes Vantive following acquisition by Carlyle funds

Vantive, formerly the Baxter Kidney Care segment, launched as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (CG) from Baxter International (BAX). The company said, “Vantive builds on a 70-year legacy as a leader in kidney care innovation to advance its mission of extending lives and expanding possibilities. As an independent company, Vantive is dedicated to elevating the standards of kidney and vital organ therapies with a vision to enable longer, fuller lives for patients everywhere. Approximately 4 million people worldwide receive dialysis treatment for chronic kidney disease. Access to this life-sustaining treatment varies across regions, and patients on dialysis often face physical and emotional burdens throughout the therapy process. Empowering patients and care teams, while helping to break down the barriers to starting and staying on therapy, is central to Vantive’s strategy to advance vital organ therapies.”